News | Wearables | February 23, 2021

RhythMedix Launches Next-Generation RhythmStar Wearable Cardiac Monitor With Built-In Cellular Connectivity

Technology designed to improve cardiac monitoring for faster arrhythmia detection

Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 

Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The cardiac telemetry monitor can be worn for extended remote monitoring without the need for an additional phone or communication device. 

February 23, 2021 — Remote cardiac monitoring vendor RhythMedix released its next-generation RhythmStar wearable device with built-in 4G cellular connectivity. The novel cardiac telemetry monitor is discreetly worn for extended remote monitoring without the need for an additional phone or communication device. 

The technology enables rapid ECG analysis and reporting of cardiac abnormalities by RhythMedix's team of U.S.-based certified technicians, who alert physicians if an arrhythmia of concern is detected. RhythmStar is now available with HeartTime™ on-demand telemetry mode, an innovative platform that allows physicians to evaluate cardiac activity and expedite care via a telemedicine appointment, limiting the need for an in-person office visit.

Heart arrhythmias are a major health concern that doubles the risk of death in an estimated 33.5 million people worldwide.[1,2] While remote cardiac monitoring has improved arrhythmia detection, patient compliance and timely access to heart activity currently limit accurate and timely diagnosis.

"The novel wearable RhythmStar monitoring device offers increased patient compliance and allows for accurate assessment of cardiac rhythm in real time," said Steven DaTorre, M.D., FACC, a clinical cardiologist at Cooper University Health Care in New Jersey. "It also allows me to remain connected to my patients throughout their monitoring period, which may expedite a life-saving diagnosis."  

The sleek, one-piece device, with built-in 4G cellular technology, is the first wearable multi-modality cardiac monitor (Holter, event and MCT) that connects patients and clinicians for improved patient care. RhythmStar integrates seamlessly into clinical practice, helping physicians make informed treatment decisions that allow patients to enjoy life, without missing a beat.

"We are excited to offer physicians and their patients our unique monitoring solution that improves patient compliance, helps accelerate diagnosis, and allows physicians to stay virtually connected to their patients with on-demand access to clinical data", stated Brian Pike, president, chief operations officer and co-founder of RhythMedix. "We look forward to bringing this next-generation RhythmStar technology to physicians across the U.S. in 2021."

For more information: www.rhythmedix.com

 

References:

1. W.B Kannel, P.A Wolf, E.J Benjamin, D Levy. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 1. The American Journal of Cardiology. DOI: https://doi.org/10.1016/S0002-9149(98)00583-9.

2. Sumeet S. Chugh, Rasmus Havmoeller, Kumar Narayanan, et al. Worldwide Epidemiology of Atrial Fibrillation. A Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. Originally published 17 Dec 2013. https://doi.org/10.1161/CIRCULATIONAHA.113.005119.
 

Related Content

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...